These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 29233789)

  • 1. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.
    Fujimoto D; Sato Y; Uehara K; Ishida K; Fukuoka J; Morimoto T; Kawachi H; Mori R; Ito M; Teraoka S; Nagata K; Nakagawa A; Otsuka K; Imai Y; Tomii K
    J Thorac Oncol; 2018 Mar; 13(3):377-386. PubMed ID: 29233789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small-cell lung cancer in clinical practice.
    Villaruz LC; Ancevski Hunter K; Kurland BF; Abberbock S; Herbst C; Dacic S
    Histopathology; 2019 Jan; 74(2):269-275. PubMed ID: 30105871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Gadgeel S; Hirsch FR; Kerr K; Barlesi F; Park K; Rittmeyer A; Zou W; Bhatia N; Koeppen H; Paul SM; Shames D; Yi J; Matheny C; Ballinger M; McCleland M; Gandara DR
    Clin Lung Cancer; 2022 Jan; 23(1):21-33. PubMed ID: 34226144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
    J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
    Tamiya A; Tamiya M; Go H; Inoue T; Kunimasa K; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Suzuki H; Hirashima T; Atagi S; Shintani A; Imamura F
    Anticancer Res; 2020 Aug; 40(8):4229-4236. PubMed ID: 32727749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.
    Zhou C; Srivastava MK; Xu H; Felip E; Wakelee H; Altorki N; Reck M; Liersch R; Kryzhanivska A; Oizumi S; Tanaka H; Hamm J; McCune SL; Bennett E; Gitlitz B; McNally V; Ballinger M; McCleland M; Zou W; Das Thakur M; Novello S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37903590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
    Munari E; Rossi G; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Netto GJ; Hoque MO; Brunelli M; Martignoni G; Haffner MC; Moretta F; Pegoraro MC; Cavazza A; Samogin G; Furlan V; Mariotti FR; Vacca P; Moretta L; Bogina G
    Am J Surg Pathol; 2018 Oct; 42(10):1384-1389. PubMed ID: 29901568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
    Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.
    Shigeta N; Murakami S; Yokose T; Isaka T; Shinada K; Nagashima T; Adachi H; Shigefuku S; Murakami K; Miura J; Kikunishi N; Watabe K; Saito H; Ito H
    Thorac Cancer; 2024 Jun; 15(17):1343-1349. PubMed ID: 38698758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
    Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY
    Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
    Adam J; Le Stang N; Rouquette I; Cazes A; Badoual C; Pinot-Roussel H; Tixier L; Danel C; Damiola F; Damotte D; Penault-Llorca F; Lantuéjoul S
    Ann Oncol; 2018 Apr; 29(4):953-958. PubMed ID: 29351573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types.
    Maule JG; Clinton LK; Graf RP; Xiao J; Oxnard GR; Ross JS; Huang RSP
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer.
    Xu H; Lin G; Huang C; Zhu W; Miao Q; Fan X; Wu B; Zheng X; Lin X; Jiang K; Hu D; Li C
    Sci Rep; 2017 Dec; 7(1):16956. PubMed ID: 29209070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
    Wang Z; Ying J; Xu J; Yuan P; Duan J; Bai H; Guo C; Li L; Yang Z; Wan R; Fei K; Zhao Z; Du X; Zhao J; Lv N; Wang J
    JAMA Netw Open; 2020 Oct; 3(10):e2013770. PubMed ID: 33017026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression.
    Miyakoshi J; Yoshida T; Kashima J; Shirasawa M; Torasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Shiraishi K; Kohno T; Yamamoto N; Yatabe Y; Suzuki T; Ohe Y
    Lung Cancer; 2024 May; 191():107788. PubMed ID: 38593478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.